Clinical Trial Management

If you’re still calling them ‘Essential Documents,’ you’re already behind. Here’s what’s changed in ICH E6 (R3)—and why it matters.  New guidance means new language—and in clinical research, wording matters.  The latest ICH E6 (R3) update introduces key terminology shifts that impact TMF management.   Here are a few key updates:  ✅ 𝗘𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗗𝗼𝗰𝘂𝗺𝗲𝗻𝘁𝘀 → Now called Essential Records      ✅ 𝗦𝘂𝗯𝗷𝗲𝗰𝘁 → Now Participant     ✅ 𝗦𝗶𝘁𝗲 → Now Location  ✅ 𝗖𝗥𝗢/𝗩𝗲𝗻𝗱𝗼𝗿 → Now Service Provider      On the surface, these seem like small changes, but they have real implications for TMF professionals.   For example, moving from Essential Documents → Essential Records reflects a 𝗯𝗿𝗼𝗮𝗱𝗲𝗿 𝘀𝗵𝗶𝗳𝘁 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁:    • We’re not just managing documents anymore—we’re managing data.  • Many records won’t exist as traditional “documents” but will be digital and dynamic.  • This change aligns with trends like digital protocol standardization (ICH M11).   Another interesting shift: The industry is moving away from rigid distinctions between CROs, vendors, and service providers.   The term Service Provider now encompasses all third-party contributors, acknowledging that these roles have evolved and overlap more than ever.   So, what does this mean for the TMF Reference Model?   👉 Expect updates in Version 4 to align with these changes. Artifact names, category structures, and definitions will evolve to match the ICH E6 (R3) framework.    If you’re responsible for TMF oversight, now is the time to familiarize yourself with these updates and ensure your organization is prepared for the shift.  What terminology change do you think will have the biggest operational impact? Let me know in the comments. ⬇️  

Here’s what a good clinical trial budget SHOULD do: SHOULD reflect the real work happening at the site SHOULD align every cost to the approved protocol SHOULD separate start-up, per-patient, and close-out costs clearly SHOULD pay investigators and coordinators for actual time spent SHOULD budget per-patient costs based on visit complexity SHOULD include ethics, regulatory, and insurance as non-negotiables SHOULD allocate 40–60% to sites and investigators SHOULD define CRO and vendor costs transparently SHOULD include a 5–15% contingency for risk SHOULD tie payments to clear milestones SHOULD prevent work before CTA execution SHOULD track actual vs forecast monthly SHOULD be amended when the protocol changes SHOULD protect quality, not just control cost SHOULD build trust between sponsors, CROs, and sites If your budget only works on paper, it won’t work in real life. Your budget is not an accounting tool. It’s a delivery tool. If you’ve worked on a trial where the budget broke the study, you already know this. Follow the Join the network channel on WhatsApp: https://lnkd.in/gsaf2Kcn

Published today in the U.S.: ICH E6(R3) #GoodClinicalPractice. Today, the #FDA has finalized and posted the modernized #GCP guideline, a big step forward for risk-proportionate, tech-enabled trials. What this means now - If you’re designing new studies, plan to align with #E6(R3) immediately. - For ongoing trials, build a proportionate transition plan (protocol, #RBQM, vendor oversight, documentation). - Expect stronger emphasis on QbD, CtQs/QTLs, centralized monitoring, and fit-for-purpose digital tools. Next steps: - Run a GCP R3 gap assessment across SOPs, templates, and training. - Update protocol templates with CtQs & QTLs; refresh RBQM/CM plans. - Tighten data governance & vendor oversight; document rationale for proportionality. - Brief teams; align KPIs to participant safety & data reliability by design. #ICH #FDA

It’s December 1st. Budgets are being tightened. Slides are being written for boards. Everyone is trying to prove they can do more with less. But here’s the uncomfortable truth: Clinical trials rarely go over budget because teams spent too much. They go over budget because they saved in the wrong places. Cut monitoring instead of cleaning the protocol. Trim vendors instead of tightening scopes. Push sites harder instead of fixing their burden. Swap experience for “cheaper” resources and pay for it three times in delays. None of these look reckless in the moment. They look responsible. Until they don’t. The smart question isn’t “Where can we cut?” It’s: “Where can we invest once so we don’t pay for it all year?” As Q1 planning is underway, the most financially efficient teams will focus on: • Fixing inefficiency instead of squeezing people • Protecting execution instead of just protecting optics • Funding first-time-right work instead of recycling work later Clinical trials are expensive. But rework is what makes them unaffordable. If there’s one lever worth pulling this quarter, it’s this: STOP paying to fix the same problem twice.

🚀 Essential Clinical Trial Documents – Part 5 🏥 Site Management – The Operational Backbone of a Clinical Trial Once a trial gets its green light from the EC and regulators, the spotlight shifts to sites — where the actual patient interaction, data capture, and protocol execution happen. To ensure high-quality execution, these Site Management Documents (as per Zone 5 of the DIA TMF Reference Model) must be in place before and during trial conduct. Let’s break down each one: ⸻ 📂 Detailed Site Management Documents & Their Importance ✅ 1. Site Selection Visit Report (SSV) ➤ A formal assessment of the site’s infrastructure, equipment, patient pool, PI experience, and GCP compliance before onboarding. 🔍 Why it matters: Ensures only capable and compliant sites are selected. ✅ 2. Site Initiation Visit Report (SIV) ➤ Documentation of training provided to site staff on protocol, GCP, EDC systems, safety reporting, etc. 📍 Key part of site readiness. ✅ 3. Site Training Logs & Certificates ➤ Record of all staff who underwent trial-specific and GCP training, including dates and trainers. 📘 Proves that staff are qualified and informed before taking on responsibilities. ✅ 4. Delegation of Authority Log (DOA) ➤ Lists all site personnel, their roles, and delegated trial duties — signed by the PI. 🖋️ A critical audit trail of who did what and when. ✅ 5. Site Signature Sheet ➤ Contains wet-ink or electronic signatures of all site personnel for verification during data reviews and audits. 🧾 Used to match signatures on forms and source data. ✅ 6. Confidentiality Agreements / Non-Disclosure Agreements (NDAs) ➤ Signed before protocol sharing to protect intellectual property and trial details. 🔒 Mandatory before sharing sensitive documents like IB or protocol. ✅ 7. Site Contact Log ➤ Log of all communication between site and sponsor/CRO (e.g., emails, calls, visits). 📞 Supports transparency and tracks issue resolutions. ✅ 8. Monitoring Visit Reports (IMV, COV, etc.) ➤ Includes follow-up letters and reports from interim and close-out monitoring visits. 📝 Helps ensure continuous oversight and site compliance. ✅ 9. Site-Specific EC Documents ➤ EC approvals for local ICFs, translated versions, recruitment materials, and site-level modifications. 🌍 Essential in multi-site and multilingual studies. ✅ 10. Lab & Vendor Documents (If site-managed) ➤ Certifications, normal value ranges, and accreditations of local labs. 🔬 Ensures lab data reliability. 📌 Why Site Management Docs Matter: Without a strong documentation trail here, trials are vulnerable to audit findings, data integrity risks, and regulatory noncompliance. 💬 A large portion of Site Management documentation is required before trial start to qualify the site and prove it is ready to begin. #ClinicalTrials #SiteManagement #TMF #ICHGCP #Monitoring #TrialSites #TMFZone5 #DelegationLog #TrainingCompliance #StudyConduct #TrialMasterFile #DIAReferenceModel

Clinical trials have come a long way. There was a time when every single data point at every site had to be manually verified—an exhaustive process that drained time, resources, and still left room for errors. For example, a global Phase III trial for a new oncology drug was struggling with delays. Sites were overwhelmed with Source Data Verification (SDV), leading to slow data entry and late issue detection. Despite high SDV rates, critical protocol deviations at certain sites were missed until much later. The study was burning through monitoring budgets with frequent but low-value site visits. 💡 Then, Risk-Based Monitoring (RBM) was introduced. Instead of verifying everything manually, the trial team used centralized monitoring and AI-driven analytics to flag high-risk sites. Targeted monitoring reduced SDV workload by 40%, allowing teams to focus on key risk indicators instead of drowning in paperwork. Early risk detection led to proactive interventions, reducing protocol deviations and improving data quality. The result? Trial timelines improved, costs were optimized, and most importantly—patient safety was enhanced. This is why RBM isn’t just a process shift—it’s a necessity. It has revolutionized clinical trials by enhancing patient safety and data integrity through targeted, data-driven strategies. A notable example is Pfizer's implementation of a systematic, proactive quality risk management process in their clinical trials. This approach involved analytical methods to evaluate and mitigate risks, leading to improved quality outcomes and operational efficiency. For a comprehensive understanding of RBM, you might find this video insightful: https://lnkd.in/g7EVyUhm How do you see RBM evolving in the coming years? Let’s discuss! #ClinicalTrials #RiskBasedMonitoring #RBM #ClinicalResearch #Pharmacy

For a Clinical Research Associate (CRA) working on clinical trials, the most effective methods involve collaboration, organization, and communication. Here’s how a CRA can optimize their work and benefit from the support of a Clinical Project Manager (CPM): Effective Methods for a CRA: 1. Maintain a Comprehensive Monitoring Plan: • Conduct regular site visits (initiation, monitoring, and close-out) as per the schedule. • Verify that site activities are in line with Good Clinical Practice (GCP), protocol, and regulatory requirements. 2. Develop Strong Relationships with Site Staff: • Build trust and rapport with site investigators, coordinators, and other staff. • Encourage open communication to quickly identify and resolve issues. 3. Accurate Data Collection and Reporting: • Ensure accurate and timely entry of data into case report forms (CRFs) and electronic systems. • Monitor the trial’s progress and compliance with the protocol by cross-verifying data with source documents. 4. Issue Resolution and Documentation: • Identify potential risks and resolve issues related to protocol deviations, patient safety, or non-compliance. • Maintain detailed records of findings and corrective actions in monitoring visit reports (MVRs). 5. Stay Organized and Updated: • Regularly review key trial documents (e.g., protocol amendments, Investigator’s Brochure, regulatory approvals). • Keep track of regulatory submissions, ethics approvals, and informed consent updates. How a CRA Can Seek Support from a Clinical Project Manager (CPM): 1. Escalation of Site Issues: • If a site experiences repeated compliance issues, delays, or high staff turnover, the CRA should inform the CPM for strategic support. • The CPM can provide guidance, escalate issues to sponsors, or authorize additional resources to resolve site challenges. 2. Protocol Clarifications: • If there are ambiguities or conflicts in the protocol, the CPM can consult with the sponsor, clinical experts, or protocol authors to provide clarification. 3. Risk Management and Decision-Making: • CRAs can seek advice from the CPM on handling high-risk situations, such as serious adverse events (SAEs) or significant protocol deviations. 4. Performance Metrics and Timelines: • The CPM tracks overall trial timelines and performance metrics. CRAs can collaborate with them to align monitoring activities with trial milestones and ensure on-time site deliverables. 5. Training and Resources: • CPMs can coordinate additional training sessions or provide resources to CRAs to ensure they are up-to-date on new processes, systems, and regulatory requirements. 6. Conflict Resolution: • CPMs can mediate and resolve conflicts between site staff, CRAs, and other stakeholders, ensuring smoother operations. By using these methods and fostering collaboration with the CPM, CRAs can improve site compliance, data integrity, and overall trial efficiency.

The EMA put a sentence in writing last month that some sponsors will read twice. [UPDATE]                                                                                                           The date in this post is wrong. I attributed the EMA Notice to Sponsors on Validation and Qualification of Computerised Systems to 8 April 2026. The original Notice was published on 7 April 2020 and was superseded by the EMA Guideline on Computerised Systems and Electronic Data in Clinical Trials, effective 9 September 2023. The source I used carried the wrong date. I did not verify it. My mistake.    This is still critical to the use of software in clinical research. These principles do not need a fresh date to be operationally critical. Any sponsor or CRO running clinical trials on vendor-supplied systems is bound by them today under the 2023 EMA Guideline, ICH E6(R3), and Annex 11. Treat the date references in the body below as historic, not current. The substance is still the right starting point. Original post continues..... "A failure to document validation may result in regulatory authorities rejecting clinical trial data for MAAs." On 8 April 2026, the EMA's GCP Inspectors Working Group issued a Notice to Sponsors on the Validation and Qualification of Computerised Systems Used in Clinical Trials. The trigger was inspection findings, not a theoretical exercise. Inspectors had been seeing inadequate validation practices and insufficient documentation of qualification activities across both sponsor-owned and vendor-supplied systems. The notice clarifies the responsibilities and the consequences. The headline for sponsors is clarity on accountability. Qualification of a computerised system can be performed by the vendor, the sponsor, or the two jointly. Validation responsibility remains with the sponsor regardless of who performed the underlying activity. Documented evidence must exist throughout the system lifecycle, from design through to decommissioning, and the sponsor must have access to it whether their team or the vendor's team built the system. The vendor agreement is now load-bearing. The notice describes "clear and formal contractual agreements between sponsors and vendors" defining validation and qualification responsibilities as essential. A handshake or a service agreement that does not name validation explicitly will not survive inspection contact. If you operate trials on computerised systems supplied or maintained by a vendor, three things to check this week: 🔹 Whether your vendor agreements explicitly name who is responsible for validation and qualification activities, and where the documentation lives 🔹 Whether your audit trail design captures both initial entries and all subsequent changes, with named users and access controls 🔹 Whether your sponsor team can produce validation evidence on request, without needing to email the vendor and wait Worth reading in full: https://lnkd.in/eWS4vixz

Ever thought about EU vs US Clinical Evidence and why there's a gap that still catches companies (and consultants) off-guard? EU MDR (2017/745) and IVDR (2017/746) are built around demonstrating safety and performance through clinical evidence that directly supports the General Safety and Performance Requirements (GSPRs). That means: > A Clinical Evaluation Report (CER) or Performance Evaluation Report (PER) linking data to intended use and claims. > Post-Market Clinical Follow-up (PMCF) or Post-Market Performance Follow-up (PMPF) with clear objectives, timelines, and triggers. > A rigorous Notified Body review that often questions equivalence justifications, literature methods, and benefit–risk linkage. In contrast, the US FDA framework is risk-driven: > PMA submissions must demonstrate reasonable assurance of safety and effectiveness through prospective clinical studies. > 510(k) notifications rely on substantial equivalence to a predicate. > De Novo requests fill the gap for novel, low-to-moderate-risk devices. Clinical expectations therefore depend more on risk profile and intended use than on a fixed template like the EU CER. Sitting between the two is ISO 14155:2020, which defines Good Clinical Practice for medical-device investigations. > It ensures data integrity, subject protection, and integration of risk-management principles from ISO 14971 throughout the study. > A study conducted under ISO 14155 is generally acceptable to BOTH the FDA and EU authorities, yet many sponsors still treat it as an afterthought rather than as the common language of clinical credibility. A simple early gap analysis - mapping MDR/IVDR expectations against FDA requirements and ISO 14155 compliance - can prevent months of rework. The most frequent weaknesses I see: > Endpoints not clearly tied to intended claims. > Literature reviews that are unsystematic or non-reproducible. > Equivalence arguments that collapse under scrutiny. > PMCF plans written once and never revisited. > Trials that meet statistical goals but not regulatory design quality. Bridging these frameworks early is not bureaucracy, and please don't let anyone tell you it is - it is actually strategic risk management. When clinical evidence, risk documentation, and labelling tell the same story, market access becomes faster....and defensible. That's the true meaning of regulatory strategy.

A Quality and Regulatory Affairs engineer asked me a question recently while preparing a Clinical Evaluation: “Can we state that a medical device has no clinical benefits? Especially when Article 61(10) is used?” This question appears often during clinical evaluation work. My short answer is simple. Under MDR, clinical benefits must be documented for medical devices. Article 2(44) defines clinical evaluation as the assessment of clinical benefits and risks associated with the device. This concept appears across the regulation: • Article 2 definitions • Article 62 on clinical investigations • Annex XIV on clinical evaluation requirements Sometimes confusion appears when the device does not deliver a direct patient benefit. For example: A device integrated into a clinical workflow A monitoring component within a system A software module supporting decision-making In these situations, the benefit may look indirect. But indirect does not mean absent. When a device contributes to a clinical system, the manufacturer must demonstrate how the device performance and safety support the clinical benefit generated by that system. The relationship must be documented and traceable. Another common misunderstanding concerns Article 61(10). Article 61(10) allows justification without clinical data in specific situations. It does not remove the requirement to define and document clinical benefits. Direct benefit or indirect benefit The documentation requirement still applies. The only exception concerns products listed under Annex XVI, addressed in Article 61(9). If you are preparing a Clinical Evaluation Report or Clinical Evaluation Plan, the practical takeaway is clear. Define the clinical benefit associated with the device. Explain how the device performance contributes to that benefit. Show the link between performance, safety, and the clinical outcome. Make the reasoning explicit and traceable. The infographic in this post summarizes the MDR articles behind this requirement. Save it for your next clinical evaluation. I am curious to hear your experience. If you worked on devices with indirect clinical benefits, how did you document the link between device performance and clinical outcome? ✌️ Peace Hatem Rabeh Your Clinical Evaluation Expert & Partner #MDR #ClinicalEvaluation #MedicalDevices #RegulatoryAffairs